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home,	preemptive	vaccination)	 as	well	 as	 an	
evaluation	of	 effectiveness	of	 and	 indications	




























AAT	 in	 the	 respiratory	system	 lead	 to	gradual	







a	 local	 inflammatory	process	 in	 the	respiratory	



























variants	marked	with	 the	 initial	 letters	of	 the	
alphabet	are	characterized	by	 lower	pH	of	 the	
isoelectric	point	(a	change	to	a	more	acidic	amino	
Table 1. Indications for intravenous augmentation therapy 
with alpha-1 antitrypsin (all listed)
Severe inherited AAT deficiency emphysema
Alpha-1 antitrypsin concentration in the serum ≤ 11 µmol/L,
FEV1 after bronchodilator administration = 30−65% predicted
or annual decline in FEV1 value ≥ 50 mL/year
Never-smokers and ex-smokers only














For	 clinical	 and	practical	 purposes	AAT	
variants	have	been	divided	 into	4	classes,	de-
pending	 on	 concentration	 and	 function	 of	 a	
given	type	in	the	plasma.	The	family	of	normal	
AAT	variants	is	designated	PI*M.	These	are	the	



















mutation	 leading	 to	 substitution	 of	 glutamic	


















2. Epidemiology and clinical significance of 










blished	 in	2002,	 the	 total	number	of	patients	
with	AAT	deficiency	(taking	PI	phenotype:	ZZ,	
SZ	and	SS	 into	account)	was	estimated	at	3.4	






































deficiency	 alleles	 has	 been	 conducted	 via	 a	









3. Diagnosis of inherited alpha-1 antitrypsin 
deficiency









deficiency	always	 requires	 confirming	 it	 on	a	
molecular	 level.	A	 clear	 identification	of	 the	
protein	phenotype	or	 the	genotype	 is	 therefore	
necessary.	 It	 is	 recommended	 that	a	diagnosis	
of	AAT	deficiency	be	confirmed	by	at	least	two	
diagnostic	methods:
1)		 measurement	of	AAT	concentration	 in	 the	
serum	+	AAT	protein	phenotyping,








3.1.1. Measurement of AAT concentration
An	initial	test	performed	for	individuals	with	
suspected	deficiency	of	 this	protease	 inhibitor	
























in	case	of	 concomitant	deficiency.	 In	order	 to	
increase	diagnostic	accuracy	and	reduce	the	risk	





variant	 through	 isoelectric	 focusing	 (IEF)	 in	 
a	polyacrylamide	gel	 (pH	gradient	4.2–4.9)	 is	
a	“gold	standard”	 in	diagnosing	 the	deficiency.	
Small	 changes	 in	 the	electrolytic	dissociation	
constant	of	the	protein	allow	to	differentiate	every	
AAT	variant	except	the	“null”	variants.	
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Figure 1. Proposed diagnostic algorithm for suspected severe alpha-1 antitrypsin deficiency or other mutations causing quantitative deficiency, 
including: AAT protein phenotyping (see section 3.1.2), AAT genotyping (see section 3.1.3) and DNA sequencing (see section 3.1.4)
cosal	epithelial	cells),	as	well	as	a	blood	sample	
on	filter	paper.
3.1.4. DNA sequence analysis
DNA	sequence	analysis	allows	 to	discover	










3.2. Recommended diagnostic scheme for 
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4. Treatment and care of patients with inherited 
alpha-1 antitrypsin deficiency
4.1. Hepatological problems in children 
Accumulation	of	AAT	 in	hepatocytes	and	











examination	 typically	 reveals	 increased	 liver	
















The	 course	 of	 the	disease	 in	 children	 is	
unpredictable.	Adverse	prognostic	 factors	 are	
constantly	being	sought	in	order	to	identify	the	









ges	 in	diagnostic	 liver	biopsy.	 In	patients	with	
portal	hypertension	and	liver	cirrhosis	in	some	
cases	clinical	condition	remains	stable	long-term.	
Oher	 than	 liver	 transplantation,	 there	are	
currently	no	causal	 treatment	options	 for	AAT	
deficiency.	Preventive	methods	 applicable	 to	




fat-soluble	vitamins	 are	used	 in	 treatment	of	
cholestasis.	There	are	 reports	of	vitamin	E	be-
ing	effective	 in	early	 infancy.	 In	case	of	portal	
hypertension	 in	 the	 course	of	 liver	 cirrhosis,	
endoscopic	 treatment	of	 esophageal	varices	 is	
effective,	and	 in	patients	with	 increasing	 liver	
dysfunction	-	its	transplantation	is	effective.	In-

















and	 severe	 lower	 respiratory	 tract	 infections,	
low	socioeconomic	status,	malnutrition	and	air	
pollution.	
Exposure	 to	passive	 smoking	 is	 a	 serious	
problem	negatively	affecting	pulmonary	 func-
tion	 in	pediatric	patients	with	AAT	deficiency.	















occurred	 in	 29%.	However,	 the	 relationship	
between	AAT	deficiency	and	obstruction	of	the	


















































4.3.2. Clinical picture 



























4.3.3. Treatment of exacerbations  
of the pulmonary disease
Infective	exacerbations	of	COPD	are	a	par-
ticularly	important	clinical	problem	in	patients	







that	 is	mechanisms	of	 innate	 immunity	whose	
main	component	is	AAT.	Exacerbations	accelerate	
the	processes	of	destruction	of	lung	parenchyma.	
4.3.4. Symptomatic treatment of the pulmonary 









—		 prevention	 and	vigorous	 treatment	 of	 re-









—	 home	oxygen	 therapy,	 in	accordance	with	
generally	accepted	indications,
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—		 lung	 transplantation,	 in	 accordance	with	
generally	accepted	indications.	

















































































5.1. Main indications for diagnosing 
alpha-1 antitrypsin deficiency (Table 2)
Diagnosing	 inherited	 alpha-1	 antitrypsin	
deficiency	 is	 recommended	 in	 adult	 patients	




—	 symptomatic	 form	of	 chronic	obstructive	
pulmonary	disease,	 regardless	of	exposure	
to	tobacco	smoke,










Testing	 for	 alpha-1	 antitrypsin	deficiency	
should	also	be	performed:
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Table 2. Main indications for diagnosing alpha-1 antitrypsin deficiency
Emphysema, especially with early onset (before 45 years of age),
Symptomatic form of chronic obstructive pulmonary disease, regardless of exposure to tobacco smoke,
Bronchial asthma marked by persistent airway obstruction
Persistent airway obstruction confirmed by function tests and exposure to occupational factors or tobacco smoke, regardless of whether 
symptoms occur
Bronchiectasis of unclear etiology
Vasculitis with the presence of c-ANCAs
Liver disease of unclear etiology
Necrotizing panniculitis
Family members of confirmed alpha-1 antitrypsin deficiency patients
Individuals with family history of one of the aforementioned disorders
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